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Abstract  
Introduction: Large-volume paracentesis is one of the usual treatments for cirrhotic patients with tense 
ascites, which may cause different complications including decreased cardiac preload, suppressed renin 
angiotensin system, inactivation of sympathetic nervous system, electrolyte imbalances, etc.  
Objective: The aim of this study was to compare the effects of administrating hydroxyethyl starch (HES) and 
albumin in cirrhotic patients with tense ascites in order to reduce the paracentesis complications. 
Methods: In the present randomized clinical trial, 108 cirrhotic patients with tense ascites were enrolled. The 
patients were randomly divided into 3 groups. In group A, albumin 20% with 5 g/L dose of paracentesis fluid, 
in group B, HES 6% dissolved in saline were administered, and in group C, a combination of albumin 20% and 
HES 6% with half the dosage administrated to two other groups were prescribed. Then biochemical panel, and 
liver function tests and renal and electrolyte complications were compared between the groups.  
Results: The results obtained after intervention did not show significant differences between the groups 
regarding weight (p=0.102), heart rate and platelet count (both p=0.094), hematocrit (p=0.09), creatinine 
(p=0.421), serum sodium (p=0.743) and potassium (p=0.147), total bilirubin (p=0.375) and urine volume 
(p=0.421). Additionally, we concluded that mean arterial pressure of patients who had received albumin was 
higher than the other 2 groups (p < 0.001). 
Conclusion: The results of the present study showed the similar effects of HES and albumin in cirrhotic 
patients with tense ascites undergoing large-volume paracentesis. 
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INTRODUCTION
Ascites is defined as accumulation of more than 25 
cc liquid in the peritoneal cavity, which has various 
reasons including cirrhosis, anomaly, congestive 
heart failure, Budd-Chiari syndrome, tuberculosis, 
and pancreatitis. Ascites is one of the most common 
complication that manifests in about 60% of 
cirrhotic patients within 10 years (1, 2). Various 
treatment methods have been proposed including 
diuretics, paracentesis, and trans-jugular 
intrahepatic portosystemic shunt (TIPS) 
placement, but none improved the survival of 
cirrhotic patients (3, 4). Among the treatment 
options, paracentesis is the most common one that 
could lead to various problems in the circulatory 
system by increasing cardiac output and 
decreasing cardiac preload (5). Thus, finding other 
treatment methods for these patients is still 
necessary. Albumin is the most common protein 
found in blood and has various functions such as 
maintaining intravascular volume and colloid 
osmotic pressure, anti-oxidant, anti-inflammation, 
stabilizing endothelial wall, and might play an 
important role in treatment of ascites caused by 
cirrhosis (6-8). The effects of albumin in cirrhotic 
patients with tense ascites vary and include 
prevention of dysfunction after paracentesis, 
decreased autonomous bacterial peritonitis, 
prevention of kidney injury and increasing 
survival. On the other hand, hydroxyethyl starch 
(HES) is used for treatment and prevention of 
hypovolemia by sustaining water in the plasma and 
increasing blood volume. It has recently been used 
as plasma expander in cirrhotic patients with tense 
ascites (9). Considering the complications caused 
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by paracentesis, the need to find a safe, non-
invasive and cheap treatment method is still 
present. In addition, to the best of our knowledge, 
there are not enough prospective studies in this 
regard and moreover, contradicting results have 
been presented in this era. Therefore, the present 
study aimed to evaluate and compare the results of 
HES and albumin in cirrhotic patients with tense 




This randomized clinical trial was performed in 
Alzahra Hospital, Isfahan, Iran, from January to 
May 2017. The study protocol was approved by the 
ethical committee of Isfahan University of Medical 
Sciences and the code of 395092 was assigned to it. 
All the participants signed the written consent 
form. The authors were fully adhered to the 
Declaration of Helsinki Principles throughout the 
study. 
Study population 
Inclusion criteria consisted of cirrhotic patients 
with tense ascites that were diagnosed by the 
emergency physician based on clinical criteria and 
ultrasonography findings (including cirrhosis of 
patients and presence of ascites fluid) and referred 
to the hospital, serum creatinine <1.4 mg/dL, 
serum sodium >120 mEq/dL, giving consent for 
participation in the study. 
Having any comorbid diseases in addition to 
cirrhosis, history of gastrointestinal (GI) bleeding 
in the past 2 weeks, presence of portosystemic 
anastomosis or peritoneal shunt, receiving plasma 
expander or paracentesis in the past 10 days, 
creatinine increasing to more than 2 mg/dL during 
the study, hepatic anomaly encephalopathy, severe 
cardiac, pulmonary, and renal diseases, infectious 
disease, hypotension (systolic blood pressure 
(SBP) <80 mmHg), severe hemodynamic disorder, 
withdrawing from participation in the study and 
patients’ data not being complete were all 
considered as the exclusion criteria. 
 
Figure 1: CONSORT flowchart of studied patients 
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The eligible patients were divided into 3 groups: 
group A received albumin, group B received HES, 
and group C received a combination of albumin and 
HES. Allocation of patients was via blocks, 
therefore since our studies included 3 groups, 
blocks of 12 included 4 participants that were 
allocated to albumin group, 4 participants in HES 
group and 4 participants of albumin and HES 
group, and this pattern went on until sample size 
was reached. CONSORT flowchart of the study has 
been shown in figure 1. Overall, 114 patients with 
the diagnosis of cirrhosis with tense ascites were 
eligible and 110 cases were allocated for each 
group: 36 in albumin group, 37 in HES group and 
37 in albumin and HES group. In the end, 6 patients 
were excluded and 108 participated in the study. 
Those who prescribed the drugs were independent 
from those who gathered patient data and both 
were blind to the type of drugs prescribed 
Intervention 
Patients did not receive diuretics and vasoactive 
agents for at least 5 days before paracentesis. 
Liquid intake before paracentesis was not more 
than 115 L per day. Patients were fasting before 
paracentesis and electrolyte levels, serum 
creatinine, complete blood count (CBC), and liver 
function tests were evaluated before paracentesis. 
Ascites fluid samples were sent to the hospital 
laboratory for undergoing routine tests such as 
culture, cell count, and biochemical tests. 
Group A: Albumin 20% with 5 g/L dose of 
parasynthesized liquid (5g/L albumin in each liter 
of parasynthesized liquid) was injected 
intravenously (to prevent liquid increase in 
vessels, half of the required albumin was 
prescribed during paracentesis and the other half 
during 6-8 hours after paracentesis) (10).  
Group B: HES 6% with 5 g/L dose of 
parasynthesized liquid (5g/L HES in each liter of 
parasynthesized liquid) was injected intravenously 
(to prevent liquid increase in vessels, half of the 
required HES was prescribed during paracentesis 
and the other half during 6-8 hours after 
paracentesis) (10). 
Group C: A combination of albumin 20% and HES 
6%, with half the dose injected in groups A and B, 
was given. This means that each of the compounds 
(albumin 20 and HES 6%) were prescribed with 2.5 
g/L dose and similar to protocol A. 
Four days after paracentesis, weight, mean arterial 
pressure, heart rate, urinary output, and level of 
consciousness were evaluated. In addition, in this 
time period biochemical tests (platelet, hematocrit, 
24-hour urine volume, fasting blood sugar (FBS), 
potassium, sodium, albumin, bilirubin, and 
prothrombin time) and liver function tests were 
done for all the patients. 
The complications that manifested after 
paracentesis and were important to us included: 
renal failure defined as more than 50% increase in 
serum creatinine (> 1.5mg/dL), hyponatremia 
where sodium concentration was less than 
130mEq/dL, hyperkalemia (potassium 
concentration > 5.5mEq/dL), infection, especially 
spontaneous bacterial peritonitis, encephalopathy, 
and cardiac diseases associated with paracentesis. 
Statistical analysis 
All patient data including demographic factors and 
paraclinical symptoms were recorded in a checklist 
designed by the researcher and entered to SPSS 22 
software; statistical analyses were presented in 
descriptive and analytic sections. In the descriptive 
section, mean and standard deviation of the 
laboratory variables and frequency of side effects 
were presented as the main variable in different 
groups and all demographic and clinical data of the 
patients were reported based on descriptive 
criteria. In the analytic section, based on statistical 
assumptions, proper parametric and non-
parametric tests were applied. To analyze 
qualitative findings chi-square and for comparison 
of quantitative data independent t-test were used. 
If the initial assumptions, such as normality of data, 
were not true, non-parametric Mann-Whitney test 
was used. All tests were evaluated at 5% error level 
and p-value < 0.05 considered significant. 
RESULTS 
Finally, 108 patients completed the survey. The 
mean age of studied patients was 45.48±3.95 years 
and 62 cases (57.4%) were male. Table 1 reports 
values of the studied variables in the 3 groups of 
patients before and after intervention. The mean 
age (p=0.218) and sex ratio (p=0.767) were not 
statistically different. Before intervention, there 
was no significant difference between the groups 
regarding the variables except for prothrombin 
time index, which stayed the same after 
intervention (p=0.001).  
In the results obtained after intervention, there 
was no significant difference in the variables such 
as weight, 24-hour urine volume, bilirubin, heart 
rate, platelet, hematocrit, sodium, and potassium 
(p>0.05), but mean arterial pressure was 
significantly different in the albumin receiving 
group compared to the other 2 groups, which 
indicates that albumin is good for patients with 
hemodynamic disorders. In addition, no dangerous 
and negative side effect was detected in any of the 
groups. 
ADVANCED JOURNAL OF EMERGENCY MEDICINE. 2017; 1(1): e7 Abootalebi et al 
   
 
4 Copyright © 2017 Tehran University of Medical Sciences  
DISCUSSION 
Based on the obtained results, there was no 
significant difference between the groups 
regarding the studied variables. However, we 
concluded that in patients with hemodynamic 
disorders, albumin is a better choice. This study 
showed that prescription of HES, albumin and even 
both simultaneously has the same effects in 
treatment of cirrhotic patients with tense ascites. 
A study by Abdel-Khalek, et al. showed that in 
cirrhotic patients with tense ascites who have 
undergone paracentesis HES 6% is as effective and 
safe as albumin for prevention of renal and 
electrolyte complications and just like the current 
study they concluded that transients hypotension 
after paracentesis is more common in HES group 
(10). 
In a study performed by Alsebaey et al. it was 
shown that Terlipressin and HES have the same 
effects as low dose albumin regarding prevention 
of hemodynamic disorder following large-volume 
paracentesis, but they cost less than albumin. 
Additionally, they concluded that plasma renin 
activity in HES group increases less than the other 
groups and urinary output was significantly higher 
than baseline at the time of discharge, but there 
was no significant difference between the groups in 
this regard (11).  
Altman et al. also showed that in cirrhotic patients 
HES is tolerated better than albumin. They also 
found out that there is no difference between HES 
and albumin regarding prevention of 
complications associated with large-volume 
paracentesis. They also concluded that weight loss 
occurs less in HES group (12). Fernandez et al. 
showed that albumin, but not HES, improves the 
hemodynamic status of patients with spontaneous 
bacterial peritonitis (13). These results were 
similar to our findings, which showed that albumin 
prescription is better in patients with 
hemodynamic disorder and did not show any 
differences between HES and albumin 
administration regarding biochemical, and liver 
function tests and renal complications. 
In a meta-analysis performed by Bernardi et al. it 
was shown that albumin decreases the morbidity 
and mortality of cirrhotic patients with tense 
ascites undergoing large-volume paracentesis. In 
addition, they compared replacement treatments 
such as dextran 70, 6%, gelatin 3.5%, HES 6%, 
dextran 40, 10%, Terlipressin 3mg, saline 3.5%, 
norepinephrine 0.5-3 mg, and Midodrine 12.5 mg 
(14). These results are in line with our findings. 
However, we followed patients for a shorter period 
of time, which was one of the limitations of this 
study and there is a need for further studies and 
increased follow-up period to evaluate the patients 
regarding mortality rate with various methods. The 
results of the present study showed the similar 
positive effects of HES and albumin in cirrhotic 
patients with tense ascites undergoing large-
volume paracentesis. We concluded that in patients 
with hemodynamic disorders, albumin is better 
and based on the patients’ condition it should be 
used as an additional treatment on the side of 
standard treatment, which leads to a significantly 






HES and albumin group 
(n=36) p 
Mean ± SD 
Weight (Kg) Before 77.36 ± 12.91 81.61 ± 14.43 74.05 ± 15.09 0.081 After 72.19 ±12.71 76.16 ± 14.22 69.05 ± 14.93 0.102 
Mean arterial pressure (mmHg) Before 83.81 ± 3.09 84.35 ± 2.41 84.16 ± 1.90 0.651 After 84.67 ± 2.59 82.24 ± 2.43 80.56 ± 3.05 <0.001 
Heart rate (/min)  Before 80.11 ± 6.49 78.33 ± 5.70 81.55 ± 6.76 0.102 After 77.05 ± 5.72 74.61 ± 5.49 77.5 ± 6.69 0.094 
Platelet count (/mm3) Before 250.14 ± 57.1 226.78 ± 61.47 228.86 ± 81.87 0273 After 301.41 ± 61.11 273.52 ± 61.12 275.66 ± 82.29 0.166 
Hematocrit (%) Before 36.68 ± 3.32 37.13 ± 3.30 35.29 ± 4.34 0.093 After 38.05 ± 3.34 38.49 ± 3.33 36.63 ± 4.35 0.09 
Serum sodium (mEq/L) Before 135 ± 2.98 134.67 ± 2.96 134.75 ± 3.43 0.896 After 134.16 ± 3.07 133.58 ± 3.05 133.88 ± 3.47 0.743 
Serum potassium (mEq/L) Before 4.36 ± 0.32 4.46 ± 0.32 4.28 ± 0.36 0.094 After 4.21 ± 0.32 4.30 ± 0.34 4.13 ± 0.38 0.147 
Total bilirubin (mg/dL) Before 5.76 ± 1.57 6.22 ± 1.99 5.75 ± 2.11 0.494 After 4.3 ± 1.59 4.88 ± 2.02 4.35 ± 2.15 0.375 
Prothrombin time index (%) Before 62.22 ± 14.17 70.44 ± 8.85 63.97 ± 12.43 0.011 After 59.5 ± 13.96 67.63 ± 8.67 61.22 ± 12.15 0.011 
Urine volume (ml/day) Before 1065.37 ± 282.54 1044.44 ± 257.67 1129.16 ± 268.69 0.385 After 1358.33 ± 281.7 1358.33 (±287.72) 1434.72 (±281.02) 0.421 
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better control of biochemical and liver function 
tests and renal and electrolyte complications. 
Limitations  
Since there are many items on the exclusion 
criteria of this study (so that the results of the study 
will not be affected and confounding factors are 
eliminated) it is difficult to generalize the afore-
mentioned findings to emergency patients. 
Therefore, it is suggested to carry out a study with 
a bigger sample size and include patients with 
various clinical statuses to generalize the findings 
of the study and evaluate the effects of the drugs 
applied in this study more accurately. Among other 
limitations of the study is the lack of long-term 
evaluation of the drugs’ effects (1 week and 1 
month later) regarding need for re-admission, or 
re-injection of the drug and the required dose to 
determine the real effects of both drugs. Therefore, 
another study is suggested to evaluate and follow 
the patients for a long period of time. 
CONCLUSIONS 
The results of the present study showed the similar 
effects of HES and albumin in cirrhotic patients 
with tense ascites undergoing large-volume 
paracentesis. Therefore, it can be concluded that 
albumin should better be prescribed for patients 
with hemodynamic disorders based on the status 
of the patients and as an adjunct treatment in 
addition to standard treatment. 
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